Newsletter Tool

To view this email as a web page, click here

Today's Rundown

Moderna COVID-19 vaccine passes FDA reviewers' test, but shares drop anyway
GoodRx: COVID-19 worsening behavioral health conditions
Biogen superspreader meeting spawned 300,000-plus U.S. coronavirus cases: study
Ex-FDA chief Gottlieb pushes for antibody manufacturing scale up as 2021 pandemic 'insurance policy'
Pfizer/BioNTech weren't alone: Moderna COVID-19 vaccine data targeted in EMA cyberattack
Biopharma roundup: Lilly looks to $1B-plus COVID payout in 2020; Ex-FDA chief Gottlieb presses U.S. to boost antibody production
Healthcare roundup: AHA, AMA call for health professionals to get vaccine
Lilly eyes up to $2B in COVID-19 sales by year-end—plus revenue boosts in cancer, diabetes and more

Featured Story

Moderna COVID-19 vaccine passes FDA reviewers' test, but shares drop anyway

By Amirah Al Idrus

Moderna’s COVID-19 vaccine is checking the boxes en route to an emergency nod. FDA staffers endorsed the shot as safe and effective in briefing documents published (PDF) on Tuesday, ahead of a COVID-19 vaccine advisory committee meeting scheduled for Thursday.

GoodRx: COVID-19 worsening behavioral health conditions

By Paige Minemyer

The pandemic is having a significant impact on people who were already living with behavioral health conditions prior to the spread of the virus, new data from GoodRx show.

Biogen superspreader meeting spawned 300,000-plus U.S. coronavirus cases: study

By Eric Sagonowsky

Even as headlines raised alarms about coronavirus breaking out in the U.S. early this year, many events still went on—and Biogen's February management conference was one calamitous example. Just how calamitous? Researchers have now linked the event with hundreds of thousands of U.S. cases.

Ex-FDA chief Gottlieb pushes for antibody manufacturing scale up as 2021 pandemic 'insurance policy'

By Fraiser Kansteiner

The U.S. should invest in swiftly scaling up antibody production to buy itself an "insurance policy" against the pandemic in 2021, former FDA Commissioner Scott Gottlieb wrote in The Wall Street Journal. By paying companies to become contract manufacturers for the drugs, the U.S. could stockpile ingredients for a quick rollout next winter.

Pfizer/BioNTech weren't alone: Moderna COVID-19 vaccine data targeted in EMA cyberattack

By Angus Liu

Looks like Pfizer and BioNTech’s COVID-19 vaccine was not the sole target of the recent cyberattack at the European Medicines Agency. Moderna said Monday that hackers also breached some documents from its pre-submission discussions about its COVID shot, mRNA-1273.

Biopharma roundup: Lilly looks to $1B-plus COVID payout in 2020; Ex-FDA chief Gottlieb presses U.S. to boost antibody production

By Eric Sagonowsky,Angus Liu,Kyle Blankenship,Conor Hale,Fraiser Kansteiner

Eli Lilly is eyeing $1 billion-plus in COVID-19 sales this year. The U.S. should help boost manufacturing for antibodies like Lilly's and Regeneron's, ex-FDA chief Gottlieb said. Trump, Pence, Biden and Harris should all get vaccinated, NIAID director Fauci said. And researchers linked Biogen's superspreader conference to hundreds of thousands of COVID cases.

Healthcare roundup: AHA, AMA call for health professionals to get vaccine

By Healthcare Staff

Follow along with the latest COVID-19 news straight from the Fierce Healthcare team.

Lilly eyes up to $2B in COVID-19 sales by year-end—plus revenue boosts in cancer, diabetes and more

By Arlene Weintraub

Eli Lilly's two COVID-19 treatments will add between $1 billion and $2 billion to sales this year, the company said, driving better-than-expected earnings. But the boost isn't just from COVID, but also from core Lilly products like diabetes drug Trulicity and breast cancer treatment Verzenio.

COVID-19 Tracker